EA202092281A1 - АНТИ-PfRH5 АНТИТЕЛА И ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ФРАГМЕНТЫ - Google Patents

АНТИ-PfRH5 АНТИТЕЛА И ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ФРАГМЕНТЫ

Info

Publication number
EA202092281A1
EA202092281A1 EA202092281A EA202092281A EA202092281A1 EA 202092281 A1 EA202092281 A1 EA 202092281A1 EA 202092281 A EA202092281 A EA 202092281A EA 202092281 A EA202092281 A EA 202092281A EA 202092281 A1 EA202092281 A1 EA 202092281A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antigen
binding fragments
antibodies
compositions
pfrh5
Prior art date
Application number
EA202092281A
Other languages
English (en)
Inventor
Лиза Перселл
Original Assignee
Ридженерон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ридженерон Фармасьютикалз, Инк. filed Critical Ридженерон Фармасьютикалз, Инк.
Publication of EA202092281A1 publication Critical patent/EA202092281A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C07K16/205—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56905—Protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Данное изобретение включает антитела и их антигенсвязывающие фрагменты, которые специфически связываются с ретикулоцитсвязывающим белком-гомологом 5 Plasmodium falciparum (PfRH5), их композиции и способы получения таких антител, фрагментов и композиций. Способ и композиции для лечения, профилактики или диагностики инфекции Plasmodium falciparum и малярии также являются частью данного изобретения.
EA202092281A 2018-03-26 2019-03-22 АНТИ-PfRH5 АНТИТЕЛА И ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ФРАГМЕНТЫ EA202092281A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862648259P 2018-03-26 2018-03-26
PCT/US2019/023734 WO2019190931A1 (en) 2018-03-26 2019-03-22 Anti-pfrh5 antibodies and antigen-binding fragments thereof

Publications (1)

Publication Number Publication Date
EA202092281A1 true EA202092281A1 (ru) 2021-01-22

Family

ID=66041796

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092281A EA202092281A1 (ru) 2018-03-26 2019-03-22 АНТИ-PfRH5 АНТИТЕЛА И ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ФРАГМЕНТЫ

Country Status (17)

Country Link
US (2) US11667701B2 (ru)
EP (1) EP3774893A1 (ru)
JP (1) JP7382950B2 (ru)
KR (1) KR20200135435A (ru)
CN (1) CN112088166A (ru)
AU (1) AU2019241978A1 (ru)
BR (1) BR112020018691A2 (ru)
CA (1) CA3094981A1 (ru)
CL (1) CL2020002449A1 (ru)
CO (1) CO2020012638A2 (ru)
EA (1) EA202092281A1 (ru)
IL (1) IL277296A (ru)
MA (1) MA52175A (ru)
MX (1) MX2020009851A (ru)
PH (1) PH12020500662A1 (ru)
SG (1) SG11202008848XA (ru)
WO (1) WO2019190931A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022006370A2 (en) * 2020-07-02 2022-01-06 Mablytics, Inc. Cell-binding proteins and methods of use
CN113045653A (zh) * 2021-03-22 2021-06-29 中国人民解放军空军军医大学 抑制疟原虫感染的单克隆抗体及其制备方法和应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US5693489A (en) 1984-03-30 1997-12-02 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
FI92882C (fi) 1992-12-29 1995-01-10 Medix Biochemica Ab Oy Kertakäyttöinen testiliuska ja menetelmä sen valmistamiseksi
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2005063817A2 (en) 2003-12-22 2005-07-14 Amgen Inc. Methods for identifying functional antibodies
US7582298B2 (en) 2006-06-02 2009-09-01 Regeneron Pharmaceuticals, Inc. High affinity antibodies to human IL-6 receptor
MY162954A (en) * 2010-11-09 2017-07-31 The Walter And Eliza Hall Inst Of Medical Res Treatment and prevention of malaria
MX355944B (es) * 2012-03-16 2018-05-07 Regeneron Pharma Animales no humanos que expresan secuencias de inmunoglobulina sensibles al ph.
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
TWI646108B (zh) * 2013-08-01 2019-01-01 艾澤西公司 結合至ｃｄ３７蛋白質之抗體藥物結合物（ａｄｃ）
CN106062004A (zh) * 2013-12-17 2016-10-26 科马布有限公司 人靶标
MA40662B1 (fr) * 2014-12-23 2020-12-31 Bristol Myers Squibb Co Anticorps contre tigit
TWI710573B (zh) * 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體

Also Published As

Publication number Publication date
MX2020009851A (es) 2020-11-09
CL2020002449A1 (es) 2021-01-29
JP7382950B2 (ja) 2023-11-17
US11667701B2 (en) 2023-06-06
CA3094981A1 (en) 2019-10-03
KR20200135435A (ko) 2020-12-02
CN112088166A (zh) 2020-12-15
IL277296A (en) 2020-10-29
US20210024625A1 (en) 2021-01-28
PH12020500662A1 (en) 2021-06-28
US20230365668A1 (en) 2023-11-16
BR112020018691A2 (pt) 2021-01-05
EP3774893A1 (en) 2021-02-17
WO2019190931A1 (en) 2019-10-03
MA52175A (fr) 2021-02-17
AU2019241978A1 (en) 2020-11-05
SG11202008848XA (en) 2020-10-29
JP2021519086A (ja) 2021-08-10
CO2020012638A2 (es) 2020-10-30

Similar Documents

Publication Publication Date Title
EA202092825A1 (ru) Анти-sirpa антитела и способы их применения
ZA202004730B (en) Anti-claudin 18.2 antibodies and uses thereof
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
MX2020009366A (es) Anticuerpos anti-cd73 y usos de los mismos.
CY1122265T1 (el) Αντισωματα εναντι ταυ και χρησεις αυτων
EA202091130A1 (ru) Лиофилизованный препарат моноклонального антитела к транстиретину
EA201890305A1 (ru) Гуманизированные или химерные cd3-антитела
EA202091747A1 (ru) Составы антитела b7-h4
EA202190138A1 (ru) Анти-sirp-бета1 антитела и способы их использования
EA201792561A1 (ru) Антитела, нацеленные на морфогенетический белок кости 9 (bmp9), и способы их применения
EA202090401A1 (ru) Анти-tim-3 антитела и их применение
EA201991726A1 (ru) Гуманизированное антитело для лечения или предотвращения когнитивных расстройств, способ его получения и агент для лечения или предотвращения когнитивных расстройств с его применением
EA202190807A1 (ru) Антитела к синуклеину
EA201990010A1 (ru) Вакцина против вируса инфекционного бронхита
BR112022009317A2 (pt) Anticorpos de cd73 biparatópicos
EA201990988A1 (ru) Антитела против chikv и пути их применения
MX2021007589A (es) Anticuerpos anti il-36 y procedimientos de uso de estos.
EP4276108A3 (en) Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
EA202190647A1 (ru) Антитела к klrg1
EA201790336A1 (ru) Антитела к ангиопоэтинподобному белку 4 и способы применения
EA202190183A1 (ru) Антитела к siglec-5 и способы их применения
EA202092281A1 (ru) АНТИ-PfRH5 АНТИТЕЛА И ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ФРАГМЕНТЫ
EA202092125A1 (ru) Антитела против рецептора фолата 1 и их применения
EA202192930A1 (ru) Антитела, связывающиеся с циркумспорозоитным белком плазмодия, и их применения
MX2021004356A (es) Formulaciones de anticuerpos anti-rsv y metodos de uso de las mismas.